Definium Therapeutics, Inc. (DFTX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $19.87: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 7.2:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.33; Below-average business quality; Negative price momentum.
Definium Therapeutics (formerly MindMed, rebranded January 2026) is a clinical-stage biopharmaceutical company developing DT120 ODT (lysergide tartrate) for generalized anxiety disorder and major depressive disorder through multiple Phase 3 trials, with no approved products. The... Read more
Sell if holding. Engine safety override at $19.87: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 7.2:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.33; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 72d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Definium Therapeutics, Inc.
Latest news
- Definium Therapeutics Dosed First Patient In Ascend Phase 3 Study Of DT120 ODT (Lysergide Tartrate) For Major Depressive — benzinga May 12, 2026 positive
- 'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive — benzinga May 8, 2026 neutral
- Piper Sandler Maintains Overweight on Definium Therapeutics, Lowers Price Target to $48 — benzinga May 8, 2026 neutral
- Definium Therapeutics Q1 EPS $(0.71) Misses $(0.48) Estimate. Cash And Equivalents Of $373.4M — benzinga May 7, 2026 negative
- 9 Health Care Stocks With Whale Alerts In Today's Session — benzinga Apr 24, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineDT120 ODT10-K Item 1A: 'Our most advanced development candidate is DT120 ODT'
- HIGHSupplierCatalent Zydis ODT10-K Item 1: 'we announced an exclusive licensing agreement with Catalent for its patented Zydis® ODT technology ... exclusive rights for the use of the Zydis technology to develop all known forms of lysergide'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $19.87: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 7.2:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.33; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $18.75. Score 4.8/10, moderate confidence.
Take-profit target: $35.52 (+78.8% upside). Prior stop was $18.75. Stop-loss: $18.75.
Concentration risk — Pipeline: DT120 ODT; Concentration risk — Supplier: Catalent Zydis ODT; Quality below floor (1.9 < 4.0).
Definium Therapeutics, Inc. trades at a P/E of N/A (forward -13.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover DFTX with a consensus score of 4.3/5. Average price target: $39.
What does Definium Therapeutics, Inc. do?Definium Therapeutics (formerly MindMed, rebranded January 2026) is a clinical-stage biopharmaceutical company...
Definium Therapeutics (formerly MindMed, rebranded January 2026) is a clinical-stage biopharmaceutical company developing DT120 ODT (lysergide tartrate) for generalized anxiety disorder and major depressive disorder through multiple Phase 3 trials, with no approved products. The company had a $582.7M accumulated deficit as of December 31, 2025 and $411.6M cash estimated to fund operations into 2028.